Enanta Pharmaceuticals (ENTA) & Its Peers Critical Contrast
Enanta Pharmaceuticals (NASDAQ: ENTA) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Enanta Pharmaceuticals to related businesses based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.
Volatility and Risk
Enanta Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals’ rivals have a beta of 1.67, indicating that their average stock price is 67% more volatile than the S&P 500.
This table compares Enanta Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Enanta Pharmaceuticals Competitors||-3,679.49%||-415.69%||-47.29%|
Valuation and Earnings
This table compares Enanta Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Enanta Pharmaceuticals||$39.73 million||-$30.75 million||-43.74|
|Enanta Pharmaceuticals Competitors||$207.80 million||-$2.19 million||-0.33|
Enanta Pharmaceuticals’ rivals have higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
66.1% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 9.3% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings and price targets for Enanta Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Enanta Pharmaceuticals Competitors||790||2961||6462||145||2.58|
Enanta Pharmaceuticals presently has a consensus target price of $38.00, indicating a potential downside of 18.80%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 5.20%. Given Enanta Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Enanta Pharmaceuticals has less favorable growth aspects than its rivals.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
Receive News & Stock Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.